1. United States
2. Letter

I hope this letter finds you well. I am writing to express my deep concern regarding the accessibility and affordability of crucial medications like Wegovy, Mounjaro, Ozempic, Zepbound, and the generic semaglutide. These life-saving drugs are essential for managing obesity and related health conditions, yet many individuals are finding them increasingly out of reach due to rising costs and diminishing insurance coverage. Wegovy and other medications in this class, such as Mounjaro and Ozempic, have not only demonstrated significant efficacy in promoting weight loss but also in improving metabolic health and reducing the risk of cardiovascular diseases. In fact, Wegovy has been approved for lowering cardiovascular risk, with studies indicating that "patients receiving semaglutide had a significant reduction in major adverse cardiovascular events." The growing trend of insurance companies dropping coverage for these medications is alarming. It creates a barrier that disproportionately affects those with limited financial means, turning what should be a standard treatment into a privilege for the wealthy. This is a matter of health equity that cannot be ignored. I urge you to advocate for policies that ensure all individuals have access to these vital medications. Making Wegovy, Mounjaro, Ozempic, Zepbound, and generic semaglutide affordable and covered by insurance will not only promote healthier lifestyles but will also reduce the long-term healthcare costs associated with obesity and its complications. Healthcare should be a right for everyone, and I implore you to take decisive action on this issue to ensure that life-saving treatments are available to all. Thank you for your attention to this urgent matter. I look forward to your support in making meaningful changes that prioritize the health and well-being of our community.